Efficacy and effectiveness of artemether-lumefantrine after initial and repeated treatment in children < 5 years of age with acute uncomplicated plasmodium falciparum malaria in rural Tanzania: A randomized trial

Clinical Infectious Diseases

Volumn 52, Issue 7, 2011, Pages 873-882

  Ngasala, Billy E ^a,h,i   Malmberg, Maja ^a   Carlsson, Anja M ^a   Ferreira, Pedro E ^a,b   Petzold, Max G ^c,d   Blessborn, Daniel ^e,f   Bergqvist, Yngve ^e,f   Gil, José P ^a,b,g   Premji, Zul ^h   Björkman, Anders ^a   Mårtensson, Andreas ^a,c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF ALGARVE   (Portugal)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^e DALARNA UNIVERSITY   (Sweden)

^f UPPSALA UNIVERSITY   (Sweden)

^g BINGHAMTON UNIVERSITY   (United States)

^h MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

ⁱ NONE   (Tanzania)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; MEROZOITE SURFACE PROTEIN 2;

ABDOMINAL ANGINA; ARTICLE; ASTHMA; CHILD; CLINICAL EFFECTIVENESS; CONJUNCTIVITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENOTYPE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MUMPS; OTITIS MEDIA; OUTCOME ASSESSMENT; PARASITE CLEARANCE; PERIODONTITIS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REINFECTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN INFECTION; TANZANIA; TONSILLITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WORM INFECTION;

ANTIMALARIALS; ARTEMISININS; BLOOD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FLUORENES; FOLLOW-UP STUDIES; HUMANS; INFANT; MALARIA; MALE; PLASMODIUM FALCIPARUM; RURAL POPULATION; TANZANIA; TREATMENT OUTCOME;

EID: 79953237074     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir066     Document Type: Article

References (37)

1. World Health Organization (WHO). Guidelines for the treatment of malaria, 2nd ed. Geneva, Switzerland: WHO, 2010. Available at: http:// www.whqlibdoc.who.int/publications/2010/9789241547925-eng.pdf. Accessed 30 June 2010.
2. Makanga M, Krudsood S. The clinical efficacy of artemether/lume-fantrine (Coartem). Malar J 2009; 8(Suppl 1).5.
3. Adjei GO, Goka BQ, Binka F, Kurtzhals JA. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. Expert Rev Anti Infect Ther 2009; 7:669-681.
4. World Health Organization (WHO). Country antimalarial drug policies: by region. Geneva, Switzerland. WHO, 2010. Available at: http:// www.who.int/malaria/am-drug-policies-by-region-afro/en/in-dex.html. Accessed 30 June 2010.
5. Tanzania Ministry of Health and Social Welfare. National guidelines for malaria diagnosis and treatment. 2006.
6. Ezzet F, Mull R, Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether 1 benflumetol) in malaria patients. Br J Clin Pharmacol 1998; 46:553-561. (Pubitemid 28522119)
7. White NJ, Van Vugt M, Ezzet F. Clinical pharmacokinetics and phar-macodynamics of artemether-lumefantrine. Clin Pharmacokinet 1999; 37:105-125.
8. Price RN, Uhlemann AC, Van Vugt M, et al. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falcipa-rum malaria. Clin Infect Dis 2006; 42:1570-1577.
9. Ezzet F, Van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharma-cokinetics and pharmacodynamics of lumefantrine (benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother 2000; 44:697-704. (Pubitemid 30117964)
10. Borrmann S, Sallas WM, Machevo S, et al. The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem) for acute uncomplicated Plasmodium falciparum malaria. Trop Med Int Health 2010; 15:434-441.
11. Premji ZG, Abdulla S, Ogutu B, et al. The content of African diets is adequate to achieve optimal efficacy with fixed-dose artemether-lumefantrine: a review of the evidence. Malar J 2008; 7:244.
12. Piola P, Fogg C, Bajunirwe F, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005; 365:1467-1473. (Pubitemid 40591691)
13. Faucher JF, Aubouy A, Adeothy A, et al. Comparison of sulfadoxine-pyrimethamine, unsupervised artemether-lumefantrine, and unsupervised artesunate-amodiaquine fixed-dose formulation for uncomplicated Plas-modium falciparum malaria in Benin: a randomized effectiveness non-inferiority trial. J Infect Dis 2009; 200:57-65.
14. Checchi F, Piola P, Fogg C, et al. Supervised versus unsupervised an-timalarial treatment with six-dose artemether-lumefantrine: pharma-cokinetic and dosage-related findings from a clinical trial in Uganda. Malar J 2006; 5:59.
15. Martensson A, Stromberg J, Sisowath C, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis 2005; 41:1079-1086 (Pubitemid 41429468)
16. Hastings IM, Watkins WM, White NJ. The evolution of drug-resistant malaria: the role of drug elimination half-life. Philos Trans R Soc Lond B Biol Sci 2002; 357:505-519. (Pubitemid 34489862)
17. Nzila AM, Nduati E, Mberu EK, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting anti-folate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/ dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000; 181:2023-2028. (Pubitemid 30416167)
18. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. Malar J 2008; 7:9.
19. Sisowath C, Stromberg J, Martensson A, et al. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). J Infect Dis 2005; 191:1014-1017. (Pubitemid 40349821)
20. Sisowath C, Ferreira PE, Bustamante LY, et al. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Trop Med Int Health 2007; 12:736-742. (Pubitemid 46872790)
21. Happi CT, Gbotosho GO, Folarin OA, et al. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob Agents Chemother 2009; 53:888-895.
22. Sisowath C, Petersen I, Veiga MI, et al. In vivo selection of Plasmodium falciparum parasites carrying the chloroquine-susceptible pfcrt K76 allele after treatment with artemether-lumefantrine in Africa. J Infect Dis 2009; 199:750-757.
23. Severe falciparum malaria. World Health Organization, Communicable Diseases Cluster. Trans R Soc Trop Med Hyg 2000; 94(Suppl 1):1-90.
24. Snounou G. Genotyping of Plasmodium spp. Nested PCR. Methods Mol Med 2002; 72:103-116.
25. Veiga MI, Ferreira PE, Bjorkman A, Gil JP. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium fal-ciparum. Mol Cell Probes 2006; 20:100-104. (Pubitemid 43343722)
26. Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 2004; 364:438-447. (Pubitemid 39036891)
27. Blessborn D, Romsing S, Annerberg A, et al. Development and validation of an automated solid-phase extraction and liquid chromato-graphic method for determination of lumefantrine in capillary blood on sampling paper. J Pharm Biomed Anal 2007; 45:282-287.
28. World Health Organization 2009. Methods for surveillance of anti-malarial drug efficacy. Available at: http://www.who.int/malaria/ publications/atoz/ 9789241597531/en/index.html. Accessed 30 June 2010.
29. Arinaitwe E, Sandison TG, Wanzira H, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis 2009; 49:1629-1637.
30. Abdulla S, Sagara I, Borrmann S, et al. Efficacy and safety of arte-mether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008; 372:1819-1827.
31. Martensson A, Ngasala B, Ursing J, et al. Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. J Infect Dis 2007; 195:597-601. (Pubitemid 46214404)
32. Bassat Q, Mulenga M, Tinto H, et al. Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One 2009; 4:7871.
33. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210-2219.
34. Zongo I, Dorsey G, Rouamba N, et al. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin-piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin Infect Dis 2007; 45:1453-1461. (Pubitemid 351411875)
35. Yeka A, Dorsey G, Kamya MR, et al. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 2008; 3:2390.
36. Olliaro P, Pinoges L, Checchi F, Vaillant M, Guthmann JP. Risk associated with asymptomatic parasitaemia occurring post-antimalarial treatment. Trop Med Int Health 2008; 13:83-90. (Pubitemid 351271393)
37. Falade C, Manyando C. Safety profile of Coartem: the evidence base. Malar J 2009; 8(Suppl 1):6.